Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

volitionrx ltd - VNRX

VNRX

Close Chg Chg %
0.14 -0.00 -1.19%

Closed Market

0.14

0.00 (1.19%)

Volume: 1.77M

Last Updated:

Apr 24, 2026, 3:59 PM EDT

Trade Now

Company Overview: volitionrx ltd - VNRX

VNRX Key Data

Open

$0.14

 Day Range

0.14 - 0.14

52 Week Range

0.14 - 0.94

 Market Cap

$25.36M

Shares Outstanding

158.48M

 Public Float

127.44M

Beta

1.33

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.22

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

10.58M

  

VNRX Performance

1 Week
 
 -21.64%
 
1 Month
 
 -28.74%
 
3 Months
 
 -50.32%
 
1 Year
 
 -71.23%
 
5 Years
 
 -95.75%
 

VNRX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About volitionrx ltd - VNRX

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

VNRX At a Glance

VolitionRX Ltd.
1489 West Warm Springs Road
Henderson, Nevada 89014
Phone 1-646-650-1351 Revenue 1.73M
Industry Medical Specialties Net Income -23,357,027.00
Sector Health Technology 2025 Sales Growth 40.038%
Fiscal Year-end 12 / 2026 Employees 75
View SEC Filings

VNRX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 15.808
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.771
Enterprise Value to Sales 21.019
Total Debt to Enterprise Value 0.316

VNRX Efficiency

Revenue/Employee 23,031.787
Income Per Employee -311,427.027
Receivables Turnover 5.435
Total Asset Turnover 0.212

VNRX Liquidity

Current Ratio 0.169
Quick Ratio 0.169
Cash Ratio 0.091

VNRX Profitability

Gross Margin 28.191
Operating Margin -1,258.468
Pretax Margin -1,360.631
Net Margin -1,352.162
Return on Assets -286.576
Return on Equity N/A
Return on Total Capital 102.526
Return on Invested Capital N/A

VNRX Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -50.324
Total Debt to Total Assets 166.126
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital -34.463
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Volitionrx Ltd - VNRX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
306.39K 775.30K 1.23M 1.73M
Sales Growth
+240.30% +153.04% +59.10% +40.04%
Cost of Goods Sold (COGS) incl D&A
1.19M 1.41M 1.30M 1.24M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.19M 1.41M 1.30M 1.24M
Depreciation
1.11M 1.33M 1.30M 1.22M
Amortization of Intangibles
- 75.56K 84.91K 24.01K
COGS Growth
- +18.78% -7.75% -4.75%
Gross Income
(882.03K) (636.33K) (68.72K) 486.97K
Gross Income Growth
- +27.86% +89.20% +808.61%
Gross Profit Margin
-287.88% -82.07% -5.57% +28.19%
2022 2023 2024 2025 5-year trend
SG&A Expense
30.90M 35.35M 26.96M 22.23M
Research & Development
13.73M 18.43M 13.32M 9.05M
Other SG&A
17.17M 16.92M 13.64M 13.18M
SGA Growth
+13.27% +14.41% -23.75% -17.55%
Other Operating Expense
- - - -
-
Unusual Expense
- (240.31K) (28.76K) (205.64K)
EBIT after Unusual Expense
(31.78M) (35.75M) (27.00M) (21.53M)
Non Operating Income/Expense
1.35M 291.94K 78.59K 518.95K
Non-Operating Interest Income
125.27K 93.32K 9.95K 600
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
173.09K 221.62K 340.36K 2.49M
Interest Expense Growth
+11.09% +28.04% +53.58% +631.38%
Gross Interest Expense
173.09K 221.62K 340.36K 2.49M
Interest Capitalized
- - - -
-
Pretax Income
(30.60M) (35.68M) (27.26M) (23.50M)
Pretax Income Growth
-13.37% -16.60% +23.60% +13.77%
Pretax Margin
-9,986.71% -4,601.70% -2,209.79% -1,360.63%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(30.60M) (35.68M) (27.26M) (23.50M)
Minority Interest Expense
(329.68K) (358.00K) (290.15K) (146.30K)
Net Income
(30.27M) (35.32M) (26.97M) (23.36M)
Net Income Growth
-12.88% -16.68% +23.65% +13.39%
Net Margin Growth
-9,879.11% -4,555.53% -2,186.27% -1,352.16%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(30.27M) (35.32M) (26.97M) (23.36M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(30.27M) (35.32M) (26.97M) (23.36M)
EPS (Basic)
-0.5469 -0.4958 -0.3116 -0.2186
EPS (Basic) Growth
-7.40% +9.34% +37.15% +29.85%
Basic Shares Outstanding
55.35M 71.23M 86.53M 106.83M
EPS (Diluted)
-0.5469 -0.4958 -0.3116 -0.2186
EPS (Diluted) Growth
-7.40% +9.34% +37.15% +29.85%
Diluted Shares Outstanding
55.35M 71.23M 86.53M 106.83M
EBITDA
(30.59M) (34.58M) (25.72M) (20.50M)
EBITDA Growth
-12.52% -13.02% +25.61% +20.31%
EBITDA Margin
-9,984.48% -4,459.69% -2,085.33% -1,186.66%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 1.96
Number of Ratings 5 Current Quarters Estimate -0.035
FY Report Date 06 / 2026 Current Year's Estimate -0.092
Last Quarter’s Earnings -0.04 Median PE on CY Estimate N/A
Year Ago Earnings -0.216 Next Fiscal Year Estimate 0.117
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 5 3
Mean Estimate -0.04 -0.03 -0.09 0.12
High Estimates -0.03 -0.02 0.05 0.54
Low Estimate -0.04 -0.04 -0.15 -0.13
Coefficient of Variance -16.50 -27.22 -88.44 315.67

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 4 4
OVERWEIGHT 0 0 0
HOLD 2 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Buy Buy

Insider Actions for Volitionrx Ltd - VNRX

Date Name Shares Transaction Value
Nov 18, 2025 Cameron John Reynolds President and CEO; Director 2,554,847 Open market or private purchase of non-derivative security Non-derivative transaction at $0.35 per share 894,196.45
Oct 1, 2025 Jacob Vincent Micallef Chief Scientific Officer 398,939 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share 239,363.40
Oct 1, 2025 Salvatore Thomas Butera CEO - Volition Veterinary 332,285 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share 199,371.00
Oct 1, 2025 Rodney Gerard Rootsaert Secretary 145,075 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share 87,045.00
Oct 1, 2025 Louise Batchelor Group Chief Marketing Officer 154,282 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share 92,569.20
Oct 1, 2025 Michel Gaetan Chief Operating Officer 369,079 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share 221,447.40
Oct 1, 2025 Gael Forterre Chief Commercial Officer 160,924 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share 96,554.40

Volitionrx Ltd in the News